Melanotan 2 research: one receptor family, four different jobs, and a thin but real human dataset.

Before the details

Here is the whole mechanism in plain words. Melanotan 2 copies a hormone called alpha-MSH that your body already makes. That hormone fits into five "locks" on different cells, called melanocortin receptors. Melanotan 2 fits all five — which is why it does several unrelated things at once.

On skin pigment cells, it turns on a chain reaction that makes more melanin, so you tan without sunlight. In the brain, the same key turns down hunger and turns up sexual signaling. That is the entire story behind tanning, appetite loss, and erections from a single peptide. The human evidence is real but small: a few Phase I studies of three to twenty people for the tanning and erection effects, and mostly animal studies for the appetite and metabolic effects. What is Melanotan 2 at the level of the studies? A potent, broad-acting research peptide with a thin human dataset and a thick case-report file — both covered below.

What is Melanotan 2

Melanotan 2 is a cyclic, lactam-bridged heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid hormone the body makes from a precursor called POMC ^[1]. "Cyclic" and "lactam-bridged" mean the peptide is locked into a ring by an internal chemical bond; that ring makes it both more potent and more resistant to being broken down than the natural linear hormone ^[1]. Its molecular weight is about 1,024 daltons. It is classed as a non-selective melanocortin-receptor agonist — it activates MC1R, MC3R, MC4R, and MC5R rather than picking just one ^[1]. That breadth is the central fact of its pharmacology and the reason a tanning peptide also affects appetite and sexual function.

The melanogenesis signaling cascade (MC1R to MITF)

Pigmentation runs through a well-mapped chain. Melanotan 2 binds MC1R on a melanocyte and activates adenylyl cyclase, raising cyclic AMP (cAMP) — a universal intracellular "go" signal ^[1]. cAMP activates protein kinase A (PKA), which switches on a transcription factor called CREB, which turns up MITF, the master gene of the pigment-cell lineage ^[1]. MITF drives tyrosinase, the rate-limiting enzyme of melanin synthesis, and the cell shifts production toward eumelanin — the darker, more photoprotective pigment ^[1]. The practical result: skin and hair darkening without ultraviolet light. This is why a tan from Melanotan 2 can keep developing for weeks after the peptide itself has cleared the body — the downstream pigment machinery keeps running.

The human pigmentation and erection studies

The strongest human data is small but consistent. In a 1996 single-blind, placebo-controlled pilot Phase I study, three healthy men received escalating subcutaneous doses (0.01 to 0.025-0.03 mg/kg) every other weekday for two weeks; two of three showed increased facial, upper-body, and buttock pigmentation after only five low doses, alongside spontaneous erections lasting one to five hours and mild nausea ^[1]. These figures are study-design facts, not dosing guidance.

The erection finding was then tested directly. In a 1998 double-blind, placebo-controlled crossover study of ten men with psychogenic erectile dysfunction, a single subcutaneous dose produced clinically apparent erections in eight of ten; mean duration of greater-than-80% tip rigidity was 38.0 minutes with Melanotan 2 versus 3.0 minutes with placebo (p=0.0045), with transient nausea, stretching, and yawning that required no treatment ^[2]. A historical review places these studies in the lineage of melanocortin therapeutics and confirms Melanotan 2 as a non-selective agonist whose breadth explains its varied effects ^[3].

Appetite, metabolism, and the brain

The appetite effect is documented mainly in animals, where it is robust. In male C57BL/6J mice, microinjecting Melanotan 2 directly into the nucleus accumbens (a brain reward-and-motivation hub) at 0.1 to 1 nmol per side significantly cut food consumption in both home-cage and operant tests and reduced the effort animals would put in to obtain food — without causing taste aversion or changing metabolic rate [25 — animal study]. This maps the appetite effect to central MC4R signaling. A 2026 case report adds a real-world data point on pigment specificity: a man who self-administered Melanotan 2 developed reversible brown pigmentation of the gums and inner cheek, with the buccal pigment fading by 28 days after he stopped ^[31]. Human metabolic trials of Melanotan 2 itself have never been completed.

Melanotan, MT2, and Melanotan II — the same compound, and the limits of the evidence

Melanotan, MT2, and Melanotan II all refer to this same peptide; "Melanotan" is also used loosely for the linear analog Melanotan I, which is a different, more MC1R-selective compound. Naming aside, the honest bottom line on the evidence is this: controlled human data exist only for pigmentation and erections, in studies of three to twenty subjects ^[1][2]. No Phase II or Phase III trial has ever been completed for Melanotan 2, and it holds no approved indication anywhere ^[3]. The appetite, metabolic, and neurobehavioral findings are largely preclinical. Against that thin efficacy dataset sits a thick safety file built from case reports — which is exactly why this digest treats the melanotan 2 dangers as the headline, not the footnote.